YCBDHealthcare · Drug Manufacturers - Specialty & GenericThe 1 Wall Street analysts covering cbdMD, Inc. hold a median 12-month price target of $2 — +293.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores cbdMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on YCBD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +293.0% from it.
Of the 11 most recent actions, 4 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Maxim Group | Downgrade | Hold | — |
| 20 Aug 2025 | Maxim Group | Maintains | Buy | — |
| 22 May 2025 | Maxim Group | Maintains | Buy | — |
| 5 Oct 2023 | Maxim Group | Initiates | Buy | — |
| 18 June 2021 | Cantor Fitzgerald | Reinstates | Neutral | $4.10 → $3.25 |
| 3 Feb 2021 | Cantor Fitzgerald | Reiterates | Neutral | $4.30 → $4.10 |
| 29 Jan 2021 | Cantor Fitzgerald | Maintains | Neutral | $3.60 → $4.30 |
| 9 Sept 2020 | Benchmark | Maintains | Speculative Buy | $3.00 → $4.00 |
| 13 Aug 2020 | Cantor Fitzgerald | Maintains | Neutral | $1.80 → $3.60 |
| 18 May 2020 | Cantor Fitzgerald | Maintains | Neutral | $1.20 → $1.80 |
| 19 Dec 2019 | Benchmark | Maintains | Speculative Buy | $9.00 → $7.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YCBD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 90% of US stocks
Cheaper than 83% of US stocks
Cheaper than 74% of US stocks
Higher than 70% of US stocks
Higher than 57% of US stocks
Higher than 71% of US stocks
Higher than 21% of US stocks
Higher than 18% of US stocks
Higher than 24% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own cbdMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of cbdMD, Inc.'s (YCBD) Q3 2026 earnings call. The item consists solely of the earnings call transcript headline with no accompanying analysis or commentary.
Why it matters — A YCBD watcher would care because the earnings call transcript is the primary record of the company's latest quarterly results and management commentary.
cbdMD, Inc. announced financial results for its third fiscal quarter of 2026, ended June 30, 2026, reporting 20% year-over-year revenue growth. The results included accelerating momentum for its Oasis hemp-derived THC beverage brand and a full quarter of contribution from Bluebird Botanicals, with the company also noting advancing federal hemp legislation.
Why it matters — The reported 20% revenue growth, along with progress on federal hemp legislation, signals strengthening positioning for YCBD as it prepares to compete under pending federal regulations.
cbdMD, Inc. (NYSE American: YCBD) announced it will host a conference call at 4:20 p.m. to discuss its third quarter results for the period ending June 30, 2026. The announcement was made via PRNewswire on Aug. 10, 2026.
Why it matters — YCBD watchers would care because the conference call will provide insight into the company's third quarter financial performance.
cbdMD has publicly welcomed a proposed U.S. Senate spending bill that, if enacted, would delay federal restrictions on full-spectrum CBD and other naturally derived hemp products slated to take effect in November.
Why it matters — A delay in federal hemp restrictions could allow cbdMD to continue selling its full-spectrum products without disruption, directly affecting the company's core business.
cbdMD announced its support for the bipartisan Lawful Hemp Protection Act, introduced July 21 by Rep. Barr and Sen. Craig, aiming to fix the federal hemp definition and protect full-spectrum CBD access for consumers.
Why it matters — A YCBD watcher would care because the proposed legislation directly affects cbdMD's ability to produce and sell full-spectrum hemp-derived wellness products under federal law.
The 1 Wall Street analysts covering cbdMD, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering cbdMD, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks cbdMD, Inc. 27 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, cbdMD, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +293.0% from the last close, and Ticker Nerd's factor model ranks cbdMD, Inc. 27 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering cbdMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YCBD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
cbdMD, Inc. returned -21.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
cbdMD, Inc. is a prominent player in the cannabidiol (CBD) industry, focusing on the production and distribution of high-quality, hemp-derived CBD products.
The most recent item we track (Seeking Alpha, 14 Aug 2026): "cbdMD, Inc. (YCBD) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of cbdMD, Inc.'s (YCBD) Q3 2026 earnings call. The item consists solely of the earnings call transcript headline with no accompanying analysis or commentary.
cbdMD, Inc. is a prominent player in the cannabidiol (CBD) industry, focusing on the production and distribution of high-quality, hemp-derived CBD products. The company's main purpose is to develop a diverse range of wellness products, which include tinctures, gummies, topicals, and bath bombs, designed to enhance personal health and wellness. cbdMD stands out in the competitive CBD market by prioritizing quality and purity, utilizing industry-leading manufacturing processes and rigorous third-party testing to ensure its products are THC-free and meet stringent standards. With its headquarters in Charlotte, North Carolina, cbdMD has positioned itself as a key contributor to the rapidly growing cannabis and wellness sectors. It serves both retail and wholesale clients across various channels, including e-commerce platforms, specialty health stores, and professional sports organizations. By leveraging strategic marketing and product innovation, cbdMD, Inc. continues to play a critical role in educating consumers and expanding the acceptance of CBD as a viable health supplement.
CEO Mr. T. Ronan Kennedy · 42 employees · United States · https://www.cbdmd.com